{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-071335","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.174708+00:00","generated_at":"2026-06-01T05:15:57.576219+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Sutro Biopharma stockholders elect Lobacki, Petree; ratify EY; approve say-on-pay & ESPP amendment","bullets":["Joseph M. Lobacki re-elected with 49.6M shares For (1.4M Withheld); Daniel H. Petree re-elected with 33.4M For (17.6M Withheld).","Ernst & Young ratified as independent auditor for FY 2024: 64.6M For, 118.9K Against, 161.9K Abstain.","Non-binding advisory approval of named executive officer compensation: 50.2M For, 171.2K Against, 587.3K Abstain.","Amendment to 2018 Employee Stock Purchase Plan approved: 50.2M For, 618.7K Against, 129.4K Abstain (increase share limit + clarifying revisions)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-071335","json":"https://secwatch.observer/filing/0000950170-24-071335.json","markdown":"https://secwatch.observer/filing/0000950170-24-071335.md","text":"https://secwatch.observer/filing/0000950170-24-071335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024071335/0000950170-24-071335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024071335/stro-20240606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:15:57.576219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}